This study recommends the use of OnLife dietary supplement, which will be followed by a few day before the initiation of PACLITAXEL, for the prevention of PACLITAXEL induced neuropathy. OnLife will be continued one month after stopping chemotherapy.
This would limit the number of PACLITAXEL dose reductions and premature interruptions of this chemotherapy, thus potentially improving the results in terms of antitumor efficacy, while improving the quality of life of patients treated with weekly PACLITAXEL.
Breast cancer patient with neo-adjuvant or adjuvant management, with an indication for weekly PACLITAXEL 80 mg/m² for 12 courses.
Age ≥ 18 years
Performans Status ≤ 3 according to Karnofsky and life expectancy greater than 6 months
For patients of childbearing age, effective contraception while taking Onlife®/placebo.
Patient previously started on PACLITAXEL
Known allergy to any of the substances in the study product Onlife®/placebo (fish oil product)
Diabetes
Exogenous (Alcoholism)